VALERIO TX(EPA:ALVIO) stock Fundamental Analysis

Fundamental Rating

Overall ALVIO gets a fundamental rating of 1 out of 10. We evaluated ALVIO against 72 industry peers in the Biotechnology industry. Both the profitability and financial health of ALVIO have multiple concerns. ALVIO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALVIO had negative earnings in the past year.

ALVIO had a negative operating cash flow in the past year.

ALVIO had negative earnings in 4 of the past 5 years.

In the past 5 years ALVIO always reported negative operating cash flow.

1.2 Ratios

ALVIO has a Return On Assets of -67.00%. This is in the lower half of the industry: ALVIO underperforms 69.44% of its industry peers.

ALVIO has a Return On Equity of -488.76%. This is in the lower half of the industry: ALVIO underperforms 72.22% of its industry peers.

		Industry Rank	Sector Rank
ROA	-67%
ROE	-488.76%
ROIC	N/A

ROA(3y)-38.08%

ROA(5y)-40.32%

ROE(3y)-81.06%

ROE(5y)-87.11%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALVIO has a better Gross Margin (74.75%) than 75.00% of its industry peers.

In the last couple of years the Gross Margin of ALVIO has declined.

ALVIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	74.75%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.31%

GM growth 5Y-6.1%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALVIO does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ALVIO has been increased compared to 1 year ago.

Compared to 5 years ago, ALVIO has more shares outstanding

Compared to 1 year ago, ALVIO has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -4.05, we must say that ALVIO is in the distress zone and has some risk of bankruptcy.

ALVIO has a Altman-Z score of -4.05. This is in the lower half of the industry: ALVIO underperforms 66.67% of its industry peers.

ALVIO has a Debt/Equity ratio of 2.88. This is a high value indicating a heavy dependency on external financing.

ALVIO has a worse Debt to Equity ratio (2.88) than 68.06% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.88
Debt/FCF	N/A
Altman-Z	-4.05

ROIC/WACCN/A

WACC7.4%

2.3 Liquidity

ALVIO has a Current Ratio of 0.90. This is a bad value and indicates that ALVIO is not financially healthy enough and could expect problems in meeting its short term obligations.

The Current ratio of ALVIO (0.90) is worse than 70.83% of its industry peers.

A Quick Ratio of 0.90 indicates that ALVIO may have some problems paying its short term obligations.

ALVIO's Quick ratio of 0.90 is on the low side compared to the rest of the industry. ALVIO is outperformed by 65.28% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.9
Quick Ratio	0.9

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.63% over the past year.

ALVIO shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.18%.

The Revenue for ALVIO have been decreasing by -21.74% on average. This is quite bad

EPS 1Y (TTM)31.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.33%

Revenue 1Y (TTM)31.18%

Revenue growth 3Y0.37%

Revenue growth 5Y-21.74%

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALVIO will show a very negative growth in Earnings Per Share. The EPS will decrease by -33.68% on average per year.

ALVIO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -29.53% yearly.

EPS Next Y-136.11%

EPS Next 2Y-50.92%

EPS Next 3Y-33.68%

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-29.53%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALVIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ALVIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ALVIO's earnings are expected to decrease with -33.68% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-50.92%

EPS Next 3Y-33.68%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALVIO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VALERIO TX

EPA:ALVIO (3/7/2025, 7:00:00 PM)

0.0545

+0 (+2.83%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-25 2024-09-25

Earnings (Next)N/A N/A

Inst Owners28.6%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap8.41M

Analysts34.29

Price Target0.01 (-81.65%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-90%

PT rev (3m)-90%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)7.14%

EPS NY rev (3m)7.14%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	4.45
P/FCF	N/A
P/OCF	N/A
P/B	2.09
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.12

EYN/A

EPS(NY)-0.1

Fwd EYN/A

FCF(TTM)-0.11

FCFYN/A

OCF(TTM)-0.11

OCFYN/A

SpS0.01

BVpS0.03

TBVpS-0.1

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-67%
ROE	-488.76%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	74.75%
FCFM	N/A

ROA(3y)-38.08%

ROA(5y)-40.32%

ROE(3y)-81.06%

ROE(5y)-87.11%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.31%

GM growth 5Y-6.1%

F-Score3

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	2.88
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	6.67%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.9
Quick Ratio	0.9
Altman-Z	-4.05

F-Score3

WACC7.4%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)15.88%

Cap/Sales(5y)11.02%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)31.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.33%

EPS Next Y-136.11%

EPS Next 2Y-50.92%

EPS Next 3Y-33.68%

EPS Next 5YN/A

Revenue 1Y (TTM)31.18%

Revenue growth 3Y0.37%

Revenue growth 5Y-21.74%

Sales Q2Q%N/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-29.53%

Revenue Next 5YN/A

EBIT growth 1Y5.45%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-150%

EBIT Next 3Y-29.07%

EBIT Next 5YN/A

FCF growth 1Y-137.17%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-142.35%

OCF growth 3YN/A

OCF growth 5YN/A

VALERIO TX (ALVIO.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens